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httpicense.Abstract Background: Diabetic nephropathy (DN) is one of the most serious complications of
diabetes mellitus. Excessive activity of reninangiotensin system plays a vital role in initiation
and progression of DN. In addition, many studies have shown that inﬂammation plays a signiﬁcant
role in DN development.
Purpose: This study was performed to evaluate the renoprotective effect of aliskiren (direct renin
inhibitor) monotherapy and combination of aliskiren plus pentoxifylline (xanthine derivative) in
hypertensive-diabetic type 2 patients with DN among patients in Gaza Strip.
Methods: Forty hypertensive-diabetic type 2 patients with microalbuminurea (20–200 lg/min or
30–300 mg/24 h) were selected from UNRWA and private clinics in Gaza Strip and divided into
two groups. The ﬁrst group (n= 20) was treated with aliskiren (150 mg/day), whereas the second
group (n= 20) was treated with aliskirenpentoxifylline combination (150, 400 mg/day). All0 599 603745; fax: +970 8 282
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222 A.T. Hamed et al.patients were followed-up for nine months by measuring serum creatinine level and urinary albumin
excretion (UAE) rate before and at 3, 6 and 9 months of treatment.
Results: The results showed a signiﬁcant reduction (P< 0.05) in UAE rate among patients who
used aliskiren and aliskirenpentoxifylline combination after 6 and 9 months of treatment, where
the reduction in both groups was more pronounced at 9 months of treatment. Moreover, the results
also showed a signiﬁcant reduction (P< 0.05) in serum creatinine level after 6 and 9 months of ali-
skirenpentoxifylline combination treatment, whereas the decrease became signiﬁcant (P< 0.05)
only after 9 months of aliskiren treatment.
Conclusion: Aliskiren monotherapy and aliskirenpentoxifylline combination improved kidney
function among hypertensive-diabetic type 2 patients with DN, however, aliskirenpentoxifylline
combination had a better renoprotective effect.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Faculty of Pharmacy, Cairo University.
Open access under CC BY-NC-ND license.1. Introduction
Diabetes mellitus (DM) is a chronic metabolic disorder charac-
terized by chronic hyperglycemia due to multiple causes
including absolute insulin deﬁciency, insulin resistance, im-
paired insulin secretion or increased glucose production.1,2
DM is set to become one of the biggest health problems owing
to its microvascular and macrovascular complications and the
increase in its prevalence.3
Diabetic nephropathy (DN) is the most common microvas-
cular complication which can develop in more than 40% of
diabetic patients.4 It is a progressive kidney disease character-
ized by changes in structure and function of the kidney.5 These
changes include glomerular basement membrane (GBM) thick-
ening, glomerular and tubular hypertrophy, mesangial expan-
sion, decline in glomerular ﬁltration rate (GFR) and
proteinuria.6 The earliest clinical sign of DN is microalbumin-
uria, which is deﬁned as urinary albumin excretion (UAE) rate
of 20–200 lg/min [30–300 mg/24 h or albumin creatinine ratio
(ACR) of 30–300 mg/g].7,8
Chronic hyperglycemia is the main determinant of DN
development through four biochemical pathways: advanced
glycation end-products (AGEs) pathway, protein kinase C
(PKC) pathway, hexosamine biosynthetic pathway (HBP)
and aldose reductase (AR) pathway.9,10 Moreover, abnormal
activation of renin-angiotensin system (RAS) by chronic
hyperglycemia plays a crucial role in the development of
DN.11 Beside the vital role of angiotensin II (Ang II) in the
progression of DN via its potent effects on renal structure
and function,12 renin, the rate-limiting step of RAS, can also
initiate the development of DN by stimulating the production
of transforming growth factor-b1 (TGF-b1), plasminogen acti-
vator inhibitor-1 (PAI-1), ﬁbronectin and collagen through
activation of the extracellular signal regulated kinases 1 and
2 (ERK1/2) pathway in mesangial cells.13,14
Thus, blocking RAS by angiotensin converting enzyme
inhibitors (ACEIs), Ang II receptor blockers (ARBs) or direct
renin inhibitors (DRIs) has many advantages with respect to
renal function in patients with hypertension and type 2
DM.11 However, neither ACEIs nor ARBs, even in high doses,
can abrogate the progression of DN completely, where they
can decrease proteinuria by 30–35%.15,16 So the use of aliski-
ren which is the ﬁrst agent that inhibits renin, the rate-limiting
step in RAS may have renoprotective effects superior to those
of ACEIs and ARBs.17
In addition, recent studies have shown that immunologic
and inﬂammatory mechanisms play a signiﬁcant role in thedevelopment of DN.18,19 So drugs which have anti-inﬂamma-
tory effects can be applied for the treatment of DN. For exam-
ple, pentoxifylline, a methylxanthine derivative with signiﬁcant
anti-inﬂammatory, antiproliferative, and antiﬁbrotic proper-
ties, can reduce renal hypertrophy, UAE rate, and renal dis-
ease progression by inhibiting the accumulation of tumor
necrosis factor-a (TNF-a) and modulating interferon-c, inter-
leukin-1b (IL-1b) and IL-6.20,21
This study was intended to investigate the renoprotective
effects of aliskiren (direct renin inhibitor, DRI) and a combi-
nation of aliskiren plus pentoxifylline (xanthine derivative)
among hypertensive-diabetic type 2 patients with DN by mea-
suring UAE rate and serum creatinine levels before and every
3 months of using these drugs throughout the study period
(9 months).
2. Patients and methods
2.1. Study design
This study is a non-randomized, prospective-comparative
study in which the renoprotective effect of aliskiren mono-
therapy and aliskirenpentoxifylline combination was evalu-
ated in hypertensive-diabetic type 2 patients with diabetic
nephropathy.
2.2. Patients
2.2.1. Study population and sample size
Patients participating in the study were hypertensive-diabetic
type 2 patients with diabetic nephropathy from both genders.
The sample size was forty patients divided into two groups (each
group contained 20 patients) according to the treatment proto-
col. Theywere selected fromprivate clinics andUNRWAhealth
centers in Gaza Strip after their urinary albumin excretion
(UAE) rate and serum creatinine level were measured.
2.2.2. Selection criteria
Patients were considered eligible in this study when they met
the following criteria: (1) both genders older than 40 years.
(2) have type 2 DM with diabetic nephropathy. (3) blood pres-
sure more than 140/90. (4) urinary albumin excretion (UAE)
rate should be 20–200 lg/min or 30–300 mg/day [microalbu-
minuria stage]. (5) serum creatinine level should not be more
than 1.8 mg/dL for men and not more than 1.5 mg/dL for
women.
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Exclusion criteria were as follows: (1) underlying type 2 DM
without diabetic nephropathy. (2) non-diabetic kidney disease.
(3) any life-threatening disease such as cancer. 4)) end-stage re-
nal disease [ESRD]. (5) previous use of aliskiren or pentoxifyl-
line. (6) history of allergy to aliskiren or pentoxifylline.
2.3. Treatment protocol
Patients participating in the study (40 patients) were divided
into two groups (each group consisted of 20 patients) accord-
ing to the treatment protocol. The ﬁrst group (n= 20) was
treated with aliskiren (150 mg/day) for 9 months, whereas the
second group (n= 20) was treated with aliskirenpentoxifyl-
line combination (150, 400 mg/day) also for 9 months. All pa-
tients were able to use any oral hypoglycemic agent or insulin
therapy according to physician instructions.
2.4. Methods
2.4.1. Hematological analysis
Hematological analysis was performed for each patient before
and every 3 months of the study period (9 months). One day
before the required analysis, participants were phoned to visit
the UNRWA clinic or laboratory and they were asked to fast
for 12 h. Blood samples were drawn from peripheral circula-
tion of the patients, then these samples were labeled with
names of patients and sent immediately to the laboratory to
perform the required tests. In this study, we performed blood
analysis to measure serum creatinine level and fasting plasma
glucose (FPG) among our patients.
2.4.2. Urinalysis
Urine analysis was performed for our patients before and
every 3 months during the study period which was 9 months.
Two days before the visit, each patient was phoned to collect
his urine throughout the day (24 h) in a suitable container.
Then urine samples were taken from the patients and labeled
with their names and sent to the laboratory to measure UAE
rate for each patient.
2.4.3. Blood pressure measurement
Blood pressure was measured for all patients by the conven-
tional method with a mercury sphygmomanometer. Systolic
and diastolic blood pressures were measured for our patients
in each group before and every 3 months of treatment
throughout the study period (9 months). Before measuring, pa-
tients were rested for 10 min, then BP was measured three
times on the left arm. Finally, the average of the three readings
was recorded in the data collecting sheet for each patient.
2.4.4. Statistical analysis
The collected data were deﬁned, coded and analyzed using the
statistical package of social science (SPSS) software package
version 16. Statistical tests as frequency and distribution were
done to express our data as numbers, percentages and Pie
charts. Moreover, paired T-test was performed to compare uri-
nary albumin excretion rates and serum creatinine levels indi-
vidually in each group before and at 3, 6 and 9 months of
treatment. Signiﬁcance of the association was tested at an al-
pha value of 60.05 (P 6 0.05).3. Results
3.1. Characteristics of the study population
The total number of the study population who fulﬁlled the
selective criteria was forty patients divided into two groups
according to the drugs used. The ﬁrst group is aliskiren treated
group, in which 11 (55%) were males and 9 (45%) were fe-
males, and their age ranged from 50 to 60 years with a mean
of 55.05 ± 3.2. They had type 2 DM from 8 to 15 years with
a mean of 11.7 ± 2.2, and had hypertension from 6 to 13 years
with a mean of 9.65 ± 2.3 (Table 1). The second group which
was treated with aliskirenpentoxiphylline combination, both
genders were represented equally (10 males and 10 females)
and their age range was from 49 to 60 years with a mean of
55.55 ± 2.9. Moreover, they had type 2 DM from 8 to 15 years
with a mean of 12.05 ± 2.3, and hypertension from 7 to
13 years with a mean of 9.85 ± 2.15 (Table 1).
3.2. Effect of aliskiren treatment on UAE rate (lg/min) in
patients before and after 3, 6 and 9 months of treatment
The results in Table 2 and Fig. 1 show a statistical signiﬁcant
reduction (P< 0.05) in UAE rate after 6 and 9 months of ali-
skiren (150 mg/day) treatment, and the reduction after
9 months was more signiﬁcant than the reduction after
6 months, where it decreased from 113.50 ± 9.764 lg/min at
baseline to 112.55 ± 8.882 lg/min after 6 months and then
to 110.50 ± 9.185 lg/min after 9 months of treatment. A slight
decrease in UAE rate after 3 months of treatment
(113.25 ± 9.089 lg/min) was also noticed; however, it was
not signiﬁcant.
3.3. Effect of aliskiren treatment on serum creatinine level (mg/
dL) in patients before and after 3, 6 and 9 months of treatment
Table 3 as well as Fig. 2 demonstrate that aliskiren (150 mg/
day) treatment is associated with a statistically signiﬁcant
(P< 0.05) decrease in serum creatinine level after 9 months
of treatment only, where the creatinine level decreased to
1.308 ± 0.026 mg/dL. In contrast, the results showed that
the drug has a little effect on serum creatinine level after 3
and 6 months of treatment. To clarify, the serum creatinine le-
vel increased from 1.316 ± 0.028 mg/dL at baseline to
1.318 ± 0.031 mg/dL after 3 months, while it decreased after
6 months to 1.316 ± 0.031 mg/dL.
3.4. Effect of aliskirenpentoxiphylline combination on UAE
rate (lg/min) in patients before and after 3, 6 and 9 months of
treatment
Fig. 1 and the results shown in Table 4 indicate a statistically
signiﬁcant relationship (P< 0.05) between aliskirenpentox-
iphylline (150, 400 mg/day) combination and UAE rate after
6 and 9 months of treatment. The UAE rate decreased to
111.50 ± 10.405 lg/min and then to 107.70 ± 10.780 lg/min
after 6 and 9 months of treatment, respectively. Although there
was a decrease in the UAE rate from 113.33 ± 7.631 lg/min at
baseline to 112.55 ± 9.517 lg/min after 3 months, this de-
crease was statistically insigniﬁcant.
Table 1 Characteristics of the study population in both groups.
Variable Aliskiren group (N= 20) AliskirenPentoxiphylline group (N= 20)
Sex (11 males and 9 females) (10 males and 10 females)
Age (years) 55.05 ± 3.2 55.55 ± 2.9
Duration of DM type 2 (year) 8–15 (11.7 ± 2.2) 8–15 (12.05 ± 2.3)
Duration of HTN (year) 6–13 (9.65 ± 2.3) 7–13 (9.85 ± 2.15)
FPG (mg/dl)
Baseline 135.65 ± 3.16 133.19 ± 3.97
After 3 months 132.30 ± 4.49 131.45 ± 2.91
After 6 months 130.75 ± 4.03 129.35 ± 5.17
After 9 months 131.05 ± 4.49 130.80 ± 4.95
SBP (mmHg)
Baseline 136.05 ± 2.98 136.69 ± 3.02
After 3 months 134.95 ± 2.44 136.70 ± 2.97
After 6 months 135.60 ± 2.16 135.45 ± 4.11
After 9 months 136.05 ± 1.64 135.30 ± 2.47
DBP (mmHg)
Baseline 87.35 ± 2.06 85.62 ± 2.36
After 3 months 85.85 ± 2.06 85.80 ± 2.58
After 6 months 85.30 ± 1.49 85.10 ± 2.53
After 9 months 86.15 ± 1.69 85.40 ± 3.15
DM: diabetes mellitus, HTN: hypertension, FPG: fasting plasma glucose, SBP: systolic blood pressure, DBP:
diastolic blood pressure. Data are expressed as mean ± S.D.
Table 2 Urinary albumin excretion (UAE) rates (lg/min) in
patients before and after 3, 6 and 9 months of Aliskiren
(150 mg/day) treatment.
UAE rate (lg/min) No. Mean ± S.D. p-value*
Before aliskiren 20 113.50 ± 9.764
After 3 months 20 113.25 ± 9.089 0.102a
After 6 months 20 112.55 ± 8.882 0.019b
After 9 months 20 110.50 ± 9.185 0.000c
* p-values (P< 0.05) are calculated by paired-samples t-test.
a p-value for UAE rate before and after 3 months of treatment.
b p-value for UAE rate before and after 6 months of treatment.
c p-value for UAE rate before and after 9 months of treatment.
Table 3 Serum creatinine levels (mg/dL) in patients before
and after 3, 6 and 9 months of Aliskiren (150 mg/day)
treatment.
Serum creatinine level (mg/dL) No. Mean ± S.D. p-value*
Before aliskiren 20 1.316 ± 0.028
After 3 months 20 1.318 ± 0.031 0.835a
After 6 months 20 1.316 ± 0.031 0.432b
After 9 months 20 1.308 ± 0.026 0.044c
* p-values (P< 0.05) are calculated by paired samples t-test.
a p-value for serum creatinine levels before and after 3 months of
treatment.
b p-value for serum creatinine levels before and after 6 months of
treatment.
c p-value for serum creatinine levels before and after 9 months of
treatment.
Figure 2 Serum creatinine levels (mg/dL) among patients treated
with Aliskiren (150 mg/day) or AliskirenPentoxiphylline (150,
400 mg/day) during the study period (9 months).
Figure 1 Urinary albumin excretion (UAE) rates among
patients treated with Aliskiren (150 mg/day) or AliskirenPen-
toxiphylline (150, 400 mg/day) during the study period (9 months).
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Table 4 Urinary albumin excretion (UAE) rates (lg/min) in
patients before and after 3, 6 and 9 months of AliskirenPen-
toxiphylline (150, 400 mg/day) treatment.
UAE rate (lg/min) No. Mean ± S.D. p-value*
Before aliskirenpentoxiphylline 20 113.33 ± 7.631
After 3 months 20 112.55 ± 9.517 0.077a
After 6 months 20 111.50 ± 10.405 0.020b
After 9 months 20 107.70 ± 10.780 0.001c
* p-values (P< 0.05) are calculated by paired-samples t-test.
a p-value for UAE rate before and after 3 months of treatment.
b p-value for UAE rate before and after 6 months of treatment.
c p-value for UAE rate before and after 9 months of treatment.
Table 5 Serum creatinine levels (mg/dL) in patients before
and after 3, 6 and 9 months of AliskirenPentoxiphylline (150,
400 mg/day) treatment.
Serum creatinine level (mg/dL) No. Mean ± S.D. p-value*
Before aliskirenpentoxiphylline 20 1.319 ± 0.035
After 3 months 20 1.318 ± 0.044 0.459a
After 6 months 20 1.316 ± 0.036 0.006b
After 9 months 20 1.302 ± 0.035 0.000c
* p-values (P< 0.05) are calculated by paired-samples t-test.
a p-value for serum creatinine levels before and after 3 months of
treatment.
b p-value for serum creatinine levels before and after 6 months of
treatment.
c p-value for serum creatinine levels before and after 9 months of
treatment.
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creatinine level (mg/dL) in patients before and after 3, 6 and
9 months of treatment
Data analysis revealed a highly signiﬁcant (P< 0.01) reduc-
tion in the serum creatinine level after 6 and 9 months of aliski-
renpentoxiphylline (150, 400 mg/day) treatment when
compared with baseline value (Table 5, Fig. 2). To clarify,
the serum creatinine level decreased to 1.316 ± 0.036 mg/dL
and then to 1.302 ± 0.035 mg/dL from 1.319 ± 0.035 mg/dL
after 6 and 9 months of treatment, respectively. Although the
combination was associated with a reduction in serum creati-
nine level after 3 months of therapy, where the level decreased
from 1.319 ± 0.035 mg/dL at baseline to 1.318 ± 0.044 mg/
dL after 3 months, this decrease was not signiﬁcant.
4. Discussion
4.1. Effect of aliskiren on urinary albumin excretion (UAE) rate
throughout the study period (9 months)
Despite their renoprotective effects, both ACEIs and ARBs
cannot prevent the progression of DN completely and can in-
crease plasma renin level and its activity.16,22,23 Although renin
has been considered as the enzyme responsible for the forma-
tion of angiotensin I (Ang I) and has been thought to have no
direct biological actions, recent studies demonstrate that itplays a pivotal role in the development of DN by binding to
(Pro)renin Receptor [(P)RR] in glomerular mesangial cells.24,25
The binding of renin as well as prorenin to (P)RR stimulates
the production of TGF-b, PAI-1, ﬁbronectin, and collagen
through the angiotensin-independent extracellular signal-regu-
lated kinase 1 and 2 (ERK 1/2) pathways.13,14,26
In our study, we found that aliskiren (150 mg/day) treat-
ment signiﬁcantly (P< 0.05) reduced the UAE rate after 6
and 9 months of treatment, where it decreased from
113.50 ± 9.764 lg/min at baseline to 112.55 ± 8.882 lg/min
after 6 months, then to 110.50 ± 9.185 lg/min after 9 months
of treatment (Table 2, Fig. 1). It was clear that the reduction in
UAE rate after 9 months was more pronounced than that pro-
duced after 6 months. The most likely explanation for this re-
sult is the inhibition of the rate-limiting step in the RAS
(conversion of angiotensinogen to Ang I via renin) by aliskiren
leading to potent renoprotective effects not only by blocking
the generation of angiotensin II (Ang II) completely, but also
by inhibiting the effects produced via activation of (P)RR.27,28
In addition, aliskiren can decrease the gene expression of
(P)RR, and can alter the 3-dimensional conﬁguration of
renin.24
Recently, some studies such as Schernthaner and Persson
et al. have evaluated the renoprotective effect of aliskiren in
hypertensive-diabetic patients with DN.28,29 Persson and his
colleagues, for example, carried out a study to investigate the
antiproteinuric effect of aliskiren monotherapy in 15 patients
with type 2 DM and albuminuria.29 They found that aliskiren
treatment (300 mg/day) was associated with a signiﬁcant de-
crease in albuminuria throughout the treatment period
(28 days) when compared with baseline value, where urinary
albumin/creatinine ratio was 173 mg/g (39–1725), (median
and range) at baseline. Urinary albumin/creatinine values de-
creased by 17% after 2–4 days and by 44% after 28 days of
treatment, where it was 158 mg/g (39–1069) at the end of the
study. Although the results obtained by Persson et al. agreed
with our results, our study indicated that aliskiren treatment
signiﬁcantly reduced the UAE rate after 6 and 9 months of
treatment with smaller dose (150 mg/day) than that used in
the previous study.
4.2. Effect of aliskiren on serum creatinine level (mg/dL)
throughout the study period (9 months)
Creatinine is a chemical byproduct generated from muscle
metabolism. It is produced at a constant rate from creatine,
a compound that is made primarily in the liver and then trans-
ported to the muscles for energy production.30 Because it is re-
moved from the body by the kidneys, creatinine has been
found to be a fairly reliable indicator of kidney function.30,31
So when the kidneys become impaired for any reason, the ser-
um creatinine level rises.
The obtained results demonstrate that aliskiren (150 mg/
day) treatment is associated with a statistically signiﬁcant
(P< 0.05) decrease in serum creatinine level after 9 months
of treatment (Table 3, Fig. 2). The results showed a slight in-
crease in the level from 1.316 ± 0.028 mg/dL at baseline to
1.318 ± 0.031 mg/dL after 3 months of treatment. However,
it gradually reduced to a signiﬁcant level after 9 months of
therapy (1.308 ± 0.026 mg/dL). These results demonstrate
that aliskiren treatment can maintain renal function by reduc-
ing serum creatinine level besides its antiproteinuric effect.
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generation and inhibition of (P)RR effects which is produced
when activated by renin or prorenin. We did not compare
our ﬁndings with other studies related to aliskiren such as Pers-
son et al. and Schernthaner, because their studies did not as-
sess the effect of aliskiren on serum creatinine level during
the evaluation of its antiproteinuric effect.
4.3. Effect of aliskirenpentoxiphylline combination on urinary
albumin excretion (UAE) rate throughout the study period
(9 months)
The results of this study indicate that aliskirenpentoxiphyl-
line (150, 400 mg/day) combination signiﬁcantly (P< 0.05) re-
duced the mean UAE rate after 6 and 9 months of treatment.
The UAE rate decreased from 113.33 ± 7.761 lg/min at base-
line to 111.50 ± 10.405 lg/min after 6 and then to
107.70 ± 10.780 lg/min after 9 months of treatment (Table 4,
Fig. 1). The most possible explanation of these results is re-
lated to the mechanism by which both aliskiren and pentoxif-
ylline can produce their antiproteinuric effects. The
antiproteinuric effect of aliskiren was previously elucidated,
while the antiproteinuric effect of pentoxifylline has been ex-
plained by three probable mechanisms. First, pentoxifylline re-
duces glomerular hydraulic pressure and proteinuria by
decreasing the blood viscosity.32 Second, pentoxifylline can re-
duce hyperﬁltration and proteinuria by antagonism of adeno-
sine, where renal overproduction of adenosine is associated
with hyperﬁltration and proteinuria.32 Third, pentoxifylline re-
duces the production and secretion of tumor necrosis factor
(TNF) and monocyte chemoattractant protein-1 (MCP-1),
which play an essential role in DN pathogenesis.32,33
To date, no study had evaluated the antiproteinuric effect
of aliskirenpentoxiphylline combination. For this reason
our results are compared with the results of other studies that
have been performed to compare the antiproteinuric effect of
pentoxiphylline with other RAS inhibitors. For example Roo-
zbeh and his colleagues compared the effect of pentoxiphyl-
line-captopril combination on proteinuria with captopril
monotherapy.34 The study was carried out for 6 months, where
seventy-four patients with type 2 DM and proteinuria were
randomly assigned to two groups of 37 patients (group 1: cap-
topril 25 mg three times per day, group 2: captopril 25 mg and
pentoxiphylline 400 mg three times per day). The UAE rate
was 2786 ± 1287.5 mg/day and 2953.4 ± 1980.3 mg/day at
baseline in group 1 and 2, respectively, while it was
2018.2 ± 1088.8 mg/day in group 1, and 1314 ± 1022.7 mg/
day in group 2 at end of the study. They found that the reduc-
tion in UAE rate in group 2 was nearly three-times that of
group 1 after 6 months of treatment.
4.4. Effect of aliskirenpentoxifylline treatment on serum
creatinine level (mg/dL) throughout the study period
(9 months)
Upon analysis of our ﬁndings, we found that aliskirenpen-
toxiphylline combination had an efﬁcient effect on renal func-
tion by decreasing the serum creatinine level signiﬁcantly
(P< 0.05) not only after 9 months of treatment, but also after
6 months. To exemplify, serum creatinine level decreased from
1.319 ± 0.035 mg/dL at baseline to 1.316 ± 0.036 mg/dL andthen to 1.302 ± 0.035 mg/dL after 6 and 9 months of treat-
ment, respectively (table 5, ﬁg. 2).
As we mentioned previously, our study was the ﬁrst study
that assessed the renoprotective effect of aliskirenpentoxiph-
ylline (150, 400 mg/day) combination in hypertensive-diabetic
patients with DN, we compared our results with studies that
used pentoxiphylline in combination with ACEIs or ARBs
such as Harmankaya et al. and Roozbeh et al.34,35 Despite
the antiproteinuric effect of pentoxiphylline in combination
with ACEIs or ARBs, the results of these studies displayed
an insigniﬁcant effect on serum creatinine level for instance,
in the study carried out by Harmankaya et al. in Turkey to
investigate the antiproteinuric effect of pentoxiphylline
(600 mg/day) plus lisinopril (10 mg/day) combination among
25 hypertensive-diabetic type 2 patients with microalbuminuri-
a. After 9 months of treatment, the serum creatinine level in-
creased from 0.9 ± 02 (mg/dL) at baseline to 1.0 ± 02 (mg/
dL). Although the results of a different study performed in
2010 by Roozbeh et al. to estimate the effect of captopril-pen-
toxifylline combination on protein excretion in patients with
type 2 DM and proteinuria were different (serum creatinine le-
vel decreased from 0.994 ± 0.23 mg/dL at baseline to
0.990 ± 0.235 mg/dL after 6 months of therapy), this reduc-
tion was insigniﬁcant (P= 0.509). The real justiﬁcation of
these advantages is not clear, but we think that these effects
are related to the mechanisms by which both aliskiren and pen-
toxifylline can affect renal cells.5. Conclusion
Diabetic nephropathy (DN) is considered one of the major
DM complications, where more than 40% of diabetic patients
may develop it.4,36 Diabetic nephropathy is a progressive kid-
ney disease characterized by changes in renal glomerular and
tubular structure and function, where microalbuminuria (20–
200 lg/min or 30–300 mg/24 h) is its ﬁrst clinical sign.8
Although it is initiated by chronic hyperglycemia, many bio-
chemical mechanisms can modulate and enhance its
progression.9
At the end of the study and based on the obtained results,
we conclude the following:
1. Both aliskiren (150 mg/day) monotherapy and aliski-
renpentoxifylline (150, 400 mg/day) combination had ren-
oprotective effect among hypertensive-diabetic type 2
patients with DN. They signiﬁcantly reduced UAE rate
after 6 and 9 months of treatment and the reduction pro-
duced by both regimens after 9 months was more distinct.
2. Aliskiren (150 mg/day) monotherapy had positive effects
on serum creatinine level only after 9 months of treatment,
while treatment with aliskirenpentoxifylline combination
produced a reduction in serum creatinine level throughout
the study period (9 months) and the signiﬁcance appeared
after 6 and 9 months of treatment.
3. The use of aliskirenpentoxifylline combination shows bet-
ter and earlier renoprotective effect.6. Ethical approval
The study was approved by the Helsinki Committee of minis-
try of health-Palestine on 6/6/2011.
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